BioSpace News Archive

Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, announces data in a late-breaking poster presentation at this year’s American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting in Washington, D.C. supporting Oral Mucosal Immunotherapy as a potential new form of food allergy treatment.

Biosenta Inc. (CSE: ZRO) (the “Company” or “Biosenta”), is pleased to announce that it has entered into debt settlement agreements with certain creditors, pursuant to which the Company

Imugene Limited, a clinical stage immuno-oncology company, highlighted recent progress across the company’s immuno-oncology portfolio and provided an update on anticipated upcoming milestones.

The company Swiss Advanced Vision has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.

Intego Clinical, a full-service biometrics Clinical Research Organization (CRO) that helps leading life science companies unlock the power of clinical data, has been accepted to provide three presentations and papers at this year’s

Congela Biocosmetics, LLC. announced the acquisition of the JuveXO® brand and product line.

OmniGuide™ Holdings and UROTECH® have announced a new partnership to strengthen UROTECH’s technology portfolio for urologists.

Rejuvenate Bio today announced publication of groundbreaking research in the peer-reviewed journal Cellular Reprogramming.

Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors.

OPKO Health, Inc. plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024.